Caribou Biosciences (NASDAQ: CRBU) is a publicly traded Gene & Genome Editing Platforms company founded in 2011 and based in Berkeley, United States.
| Date | Stage | Amount | Valuation | Lead investors |
|---|---|---|---|---|
| Jul 29, 2021 | IPO | $304M | — | — |

STAT's biotech newsletter covers a range of trial and deal news, including gene therapy cancer risk and a skeptical take on AI drug discovery.

Caribou Biosciences reports its third quarter 2026 financial results.

Caribou Biosciences stock coverage pairs upcoming ASH conference presentations with a CAR-T program shutdown.

Caribou Biosciences announces presentations at the 2026 American Society of Hematology Annual Meeting.

Gene editing stocks rise after ESGCT conference data and FDA draft guidance, per a StockWatch roundup.
Caribou's core technology uses CRISPR hybrid RNA-DNA (chRDNA, pronounced 'chardonnay') guides, in which part of the conventional RNA guide is replaced with DNA. This hybrid chemistry increases the specificity of Cas9 and Cas12a editing, reducing off-target activity while supporting high-efficiency multiplex edits and multiplex gene insertions in a single cell. The platform is the basis for Caribou's allogeneic, off-the-shelf CAR-T and CAR-NK cell therapies, where multiple precise edits are needed to evade immune rejection and improve durability.
We don't have a live feed for this company's ATS. Their careers page has every open role.
View all careers ↗